Highlights

  • Proteomics International shares rose 19.35% on 8 July 2026 after the company announced a U.S. patent grant for PromarkerEndo.
  • The United States Patent and Trademark Office granted patent protection covering the company's proprietary blood test for endometriosis.
  • The patent provides U.S. intellectual property protection until March 2041, subject to grant and maintenance requirements.
  • PromarkerEndo has demonstrated high diagnostic accuracy in published clinical studies, including for early-stage endometriosis.

Proteomics International Laboratories Ltd (ASX:PIQ) shares climbed 19.35% to AUD 0.18 during the morning session on 8 July 2026 after the company announced that it had secured a United States patent for its PromarkerEndo diagnostic blood test. The stock gained AUD 0.030 on the day, although it remains down 62.24% over the past year.

The latest announcement appears favourable, with the company securing intellectual property protection in what it describes as the world's largest healthcare market. The patent supports Proteomics International's commercialisation strategy for PromarkerEndo and strengthens its position for future licensing, partnership and reimbursement discussions as the company continues advancing its precision diagnostics portfolio.

About Proteomics International

Proteomics International Laboratories is an Australian medical technology company specialising in precision diagnostics and bio-analytical services. The company focuses on proteomics, the large-scale study of proteins, to develop diagnostic tools that assist in disease detection and patient management.

Its proprietary Promarker® platform identifies protein biomarkers, or protein "fingerprints", from blood samples to distinguish between people with and without specific diseases. This biomarker discovery technology underpins several diagnostic programs, including PromarkerEndo, which is designed to support the diagnosis of endometriosis using a blood test rather than invasive surgical procedures.

The company is headquartered in Perth, Western Australia, and continues to expand its intellectual property portfolio across multiple international markets.

U.S. Patent Marks an Important Commercial Milestone

The key development announced by Proteomics International was the grant of a U.S. patent covering PromarkerEndo by the United States Patent and Trademark Office (USPTO).

The newly granted patent, titled "Endometriosis Biomarkers" (US Patent No. 12674806), protects the company's proprietary methods for diagnosing endometriosis using specific protein biomarkers measured in blood samples. The patent also covers the use of those biomarker results to assist in treatment selection.

According to the company, the protection is expected to remain in force until March 2041, subject to grant and ongoing maintenance requirements.

For Proteomics International, the patent expands its intellectual property portfolio within one of its targeted commercial markets and provides additional protection for its proprietary diagnostic technology.

Patent Supports Global Commercialisation Strategy

The United States represents one of the company's priority healthcare markets, making the latest patent an important part of its broader commercialisation strategy.

Proteomics International said the granted patent strengthens the commercial pathway for PromarkerEndo while supporting future partnership opportunities, licensing discussions and regulatory reimbursement activities.

The company is continuing to pursue patent protection across several additional jurisdictions, including Australia, Canada, China, Europe, India, Singapore and South Korea.

Before the latest announcement, PromarkerEndo had already secured granted patent protection in Japan. With the addition of the United States, Proteomics International now holds granted patents for the technology in two major international markets.

PromarkerEndo Targets a Significant Medical Need

PromarkerEndo has been developed as a non-invasive diagnostic blood test for endometriosis, a condition that affects approximately one in nine women and girls.

According to the company, current diagnosis of endometriosis typically relies on surgical laparoscopy, while patients often experience an average diagnostic delay of around seven years.

The company said its blood test aims to provide earlier screening that may help determine whether invasive surgery is required for women presenting with symptoms of endometriosis.

Proteomics International believes earlier diagnosis has the potential to improve patient outcomes while also contributing to lower healthcare costs through more timely clinical assessment.

Clinical Studies Support Diagnostic Performance

The company highlighted previously published clinical data demonstrating that PromarkerEndo achieved high diagnostic accuracy, including for women in the early stages of endometriosis.

These published studies, previously referenced in the company's ASX announcements dated 30 December 2024 and 26 May 2025, form part of the evidence supporting the patented technology.

The patented methods use specific protein biomarkers identified through the Promarker® platform. Rather than relying on genetic testing, the technology analyses protein signatures in blood samples to identify disease-related biological patterns.

Proteomics International said this approach provides an alternative method for identifying patients who may have endometriosis.

United States Market Represents Key Opportunity

The company noted that the United States is the world's largest healthcare market and continues to experience growing demand for non-invasive diagnostic technologies that improve patient care while helping reduce healthcare costs.

Within that context, the newly granted patent provides legal protection for PromarkerEndo in a market where commercial partnerships and licensing opportunities can play an important role in product adoption.

The company believes securing patent protection in this jurisdiction is a significant step in supporting future commercial discussions surrounding the technology.

Chief Executive Officer and Managing Director David Morris described the patent grant as an important validation of both the novelty and commercial potential of PromarkerEndo.

He also stated that securing intellectual property protection in the United States strengthens the company's position for future partnership discussions, licensing opportunities and reimbursement-related activities.

Intellectual Property Portfolio Continues to Expand

The latest announcement also reflects Proteomics International's broader strategy of building patent protection across multiple international markets.

The company confirmed that patent applications remain active across several key jurisdictions, while granted protection has now been secured in both Japan and the United States.

Expanding patent coverage is an important component of the company's commercial approach, as it seeks to protect proprietary technology while supporting future commercial agreements in different healthcare markets.

The latest U.S. patent therefore adds another layer of intellectual property protection around PromarkerEndo as the company progresses its commercial activities.

Technology Built on the Promarker® Platform

PromarkerEndo has been developed using Proteomics International's proprietary Promarker® biomarker discovery platform.

The platform analyses proteins present in blood samples to identify biological patterns associated with disease. According to the company, this protein-based approach provides a powerful alternative to traditional genetic testing and supports the development of precision diagnostic tools across multiple disease areas.

PromarkerEndo represents one of the key applications of this technology, with the objective of improving the diagnosis of endometriosis through a simple blood-based assessment.

What This Means for Investors

Proteomics International's latest announcement appears to have supported the 19.35% rise in its share price on 8 July 2026, as investors responded to the company's successful U.S. patent grant for PromarkerEndo. The patent strengthens the company's intellectual property portfolio in a major healthcare market and supports its commercialisation strategy, including future licensing and partnership opportunities. Investors are also likely to monitor the company's progress in securing additional international patent protection and advancing the commercial rollout of PromarkerEndo across targeted healthcare markets.

FAQs